C. Haioun

发表

p53 gene mutations are associated with poor survival in low and low-intermediate risk diffuse large B-cell lymphomas.

P. Gaulard, G. Salles, F. Berger, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

Recurrent somatic mutations of PTPN1 in primary mediastinal B cell lymphoma and Hodgkin lymphoma

R. Gascoyne, P. Gaulard, J. Connors, 2014, Nature Genetics.

Molecular Diagnosis of Primary Mediastinal B Cell Lymphoma Identifies a Clinically Favorable Subgroup of Diffuse Large B Cell Lymphoma Related to Hodgkin Lymphoma

L. Staudt, A. Rosenwald, Xin Yu, 2003, The Journal of experimental medicine.

Report on the First International Workshop on interim-PET scan in lymphoma

Michel Meignan, C. Haioun, A. Gallamini, 2009, Leukemia & lymphoma.

Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study.

J. Rossi, G. Salles, R. Bouabdallah, 2008, Blood.

Early 18F-FDG PET for Prediction of Prognosis in Patients with Diffuse Large B-Cell Lymphoma: SUV-Based Assessment Versus Visual Analysis

Emmanuel Itti, Michel Meignan, Alain Luciani, 2007, Journal of Nuclear Medicine.

An international confirmatory study of the prognostic value of early PET/CT in diffuse large B-cell lymphoma: comparison between Deauville criteria and ΔSUVmax

H. Tilly, B. Siegel, C. Haioun, 2013, European Journal of Nuclear Medicine and Molecular Imaging.

Prognostic significance of survivin expression in diffuse large B-cell lymphomas.

J Diebold, T. Molina, P. Gaulard, 2000, Blood.

Targeting intratumoral B cells with rituximab in addition to CHOP in angioimmunoblastic T-cell lymphoma. A clinicobiological study of the GELA

P. Gaulard, G. Salles, R. Bouabdallah, 2012, Haematologica.

Obinutuzumab combined with lenalidomide for relapsed or refractory follicular B-cell lymphoma (GALEN): a multicentre, single-arm, phase 2 study.

R. Houot, G. Salles, R. Bouabdallah, 2019, The Lancet. Haematology.

Obinutuzumab versus Rituximab in young patients with advanced DLBCL, a PET-guided and randomized phase 3 study by LYSA.

T. Molina, J. Jais, P. Feugier, 2020, Blood.

Lenalidomide in combination with R-CHOP (R2-CHOP) as first-line treatment of patients with high tumour burden follicular lymphoma: a single-arm, open-label, phase 2 study.

T. Molina, F. Jardin, G. Salles, 2018, The Lancet. Haematology.

Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial

Andrew Lister, Anne Sonet, Hervé Tilly, 2011, The Lancet.

Updated 6 Year Follow-Up Of The PRIMA Study Confirms The Benefit Of 2-Year Rituximab Maintenance In Follicular Lymphoma Patients Responding To Frontline Immunochemotherapy

A. Hagenbeek, G. Salles, A. López-Guillermo, 2013 .

Optimization of whole-body 2-[18F]FDG-PET/MRI imaging protocol for the initial staging of patients with myeloma

A. Luciani, C. Haioun, E. Itti, 2021, European Radiology.

Whole-body diffusion magnetic resonance imaging in the assessment of lymphoma

Emmanuel Itti, Michel Meignan, Alain Luciani, 2012, Cancer imaging : the official publication of the International Cancer Imaging Society.

Use of Model-Based Iterative Reconstruction (MBIR) in reduced-dose CT for routine follow-up of patients with malignant lymphoma: dose savings, image quality and phantom study

A. Luciani, A. Rahmouni, J. Deux, 2015, European Radiology.

R-CHOP14 Compared to R-CHOP21 in Elderly Patients with Diffuse Large B-Cell Lymphoma: Results of the Interim Analysis of the LNH03-6B GELA Study

T. Molina, G. Salles, H. Tilly, 2009 .

Cutaneous lymphomas other than mycosis fungoides: follow-up study of 52 patients.

C. Haioun, F. Reyes, J. Revuz, 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18F]-FDG positron imaging in clinical management of lymphoma patients.

J. Talbot, C. Haioun, M. Meignan, 2001, Critical reviews in oncology/hematology.

Impact of high-dose chemotherapy on peripheral T-cell lymphomas.

P. Gaulard, C. Gisselbrecht, N. Mounier, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

SGN-30 (Anti-CD30 monoclonal antibody) is active and well tolerated in patients with refractory or recurrent systemic anaplastic large cell lymphoma (ALCL)

J. Leonard, B. Cheson, C. Haioun, 2004 .

Single-agent activity of phosphatidylinositol 3-kinase inhibition with copanlisib in patients with molecularly defined relapsed or refractory diffuse large B-cell lymphoma

G. Salles, G. Lenz, K. Ardeshna, 2020, Leukemia.

Value of [18F]fluorodeoxyglucose-positron emission tomography in managing patients with aggressive non-Hodgkin's lymphoma.

A. Rahmouni, C. Haioun, F. Reyes, 2006, Clinical lymphoma & myeloma.

Rituximab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy.

C. Copie-Bergman, J. Jais, A. Rahmouni, 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

Recurrent mutations of the exportin 1 gene (XPO1) and their impact on selective inhibitor of nuclear export compounds sensitivity in primary mediastinal B‐cell lymphoma

C. Copie-Bergman, T. Molina, F. Jardin, 2016, American journal of hematology.

Whole-Body Diffusion-Weighted Imaging With Apparent Diffusion Coefficient Mapping for Treatment Response Assessment in Patients With Diffuse Large B-Cell Lymphoma: Pilot Study

Emmanuel Itti, Michel Meignan, Alain Luciani, 2011, Investigative radiology.

Rituximab versus observation after high-dose consolidative first-line chemotherapy with autologous stem-cell transplantation in patients with poor-risk diffuse large B-cell lymphoma.

B. Coiffier, H. Tilly, C. Gisselbrecht, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Benefit of rituximab combined to ACVBP (R-ACVBP) over ACVBP in 209 poor- risk BDLC NHL patients treated with up-front consolidative autotransplantation: A GELA phase II trial (LNH 2003-3).

B. Coiffier, O. Casasnovas, P. Feugier, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Management of relapsed or refractory follicular lymphoma patients in daily practice – a French non-interventional study

G. Salles, P. Feugier, C. Haioun, 2018, Leukemia & lymphoma.

Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Diffuse Large B-Cell Lymphoma: An Individual Patient-Level Analysis of Multiple Randomized Trials (SEAL).

M. Ziepert, N. Schmitz, C. Flowers, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic value of baseline total metabolic tumor volume (TMTV0) measured on FDG-PET/CT in patients with peripheral T-cell lymphoma (PTCL).

P. Gaulard, R. Hustinx, O. Casasnovas, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Report on the 4th International Workshop on Positron Emission Tomography in Lymphoma held in Menton, France, 3–5 October 2012

S. Barrington, C. Haioun, A. Gallamini, 2014, Leukemia & lymphoma.

Whole body MRI and PET/CT in haematological malignancies

A. Luciani, A. Rahmouni, C. Haioun, 2007, Cancer imaging : the official publication of the International Cancer Imaging Society.

Early Interim PET Scans in Diffuse Large B-Cell Lymphoma: Can There Be Consensus About Standardized Reporting, and Can PET Scans Guide Therapy Choices?

D. Huglo, C. Haioun, M. Meignan, 2012, Current Hematologic Malignancy Reports.

Promising Efficacy with the New Anti-CD20 Antibody GA101 In Heavily Pre-Treated NHL Patients – First Results From a Phase II Study In Patients with Relapsed/Refractory DLBCL and MCL

G. Salles, R. Bouabdallah, P. Feugier, 2010 .

10 Years Follow-up of the GELA LNH98.5 Study, First Randomized Study Comparing R-CHOP to CHOP Chemotherapy in Patients with Diffuse Large B-Cell Lymphoma.

G. Salles, B. Coiffier, R. Bouabdallah, 2009 .

The Prognostic Impact of CD163-Positive Macrophages in Follicular Lymphoma: A Study from the BC Cancer Agency and the Lymphoma Study Association

R. Gascoyne, D. Scott, G. Salles, 2015, Clinical Cancer Research.

A phase II study of the oral JAK1/JAK2 inhibitor ruxolitinib in advanced relapsed/refractory Hodgkin lymphoma

A. Stamatoullas, M. Copin, O. Casasnovas, 2018, Haematologica.

MRI and PET of bone marrow in lymphoproliferative diseases

A. Luciani, A. Rahmouni, C. Haioun, 2003, Cancer Imaging.

A Dose-Escalation Study of SAR3419, an Anti-CD19 Antibody Maytansinoid Conjugate, Administered by Intravenous Infusion Once Weekly in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

R. Houot, B. Coiffier, H. Tilly, 2013, Clinical Cancer Research.

Integrative analysis of a phase 2 trial combining lenalidomide with CHOP in angioimmunoblastic T-cell lymphoma.

P. Gaulard, R. Bouabdallah, O. Casasnovas, 2021, Blood Advances.

Outcomes after first-line immunochemotherapy for primary mediastinal B cell lymphoma patients: a LYSA study.

R. Houot, F. Jardin, H. Tilly, 2021, Blood advances.

Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b-2 study.

G. Salles, K. Kolibaba, H. Tilly, 2019, The Lancet. Oncology.

Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma: results from the phase II BRISMA/IELSG36 study

E. Iannitto, M. Federico, C. Tripodo, 2018, British journal of haematology.

Reply to H.J.A. Adams et al and E. Laffon et al.

G. Salles, M. Federico, H. Tilly, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

European phase II study of mogamulizumab, an anti-CCR4 monoclonal antibody, in relapsed/refractory peripheral T-cell lymphoma

E. González-Barca, F. d'Amore, J. Radford, 2016, Haematologica.

Low Serum Vitamin D Levels Are Associated With Inferior Survival in Follicular Lymphoma: A Prospective Evaluation in SWOG and LYSA Studies.

G. Salles, J. Friedberg, L. Rimsza, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Rituximab, alkylating agents or combination therapy for gastric mucosa‐associated lymphoid tissue lymphoma: a monocentric non‐randomised observational study

A. Amiot, I. Sobhani, C. Copie-Bergman, 2014, Alimentary pharmacology & therapeutics.

Sarcoidosis Occurring After Lymphoma

C. Haioun, L. Mouthon, F. Maurier, 2014, Medicine.

Response assessment after an inductive CHOP or CHOP-like regimen with or without rituximab in 103 patients with diffuse large B-cell lymphoma: integrating 18fluorodeoxyglucose positron emission tomography to the International Workshop Criteria.

C. Copie-Bergman, A. Rahmouni, C. Gisselbrecht, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Bone marrow involvement in diffuse large B-cell lymphoma: correlation between FDG-PET uptake and type of cellular infiltrate

P. Gaulard, C. Haioun, M. Meignan, 2009, European Journal of Nuclear Medicine and Molecular Imaging.

Second cancers and late toxicities after treatment of aggressive non-Hodgkin lymphoma with the ACVBP regimen: a GELA cohort study on 2837 patients.

P. Gaulard, B. Coiffier, H. Tilly, 2003, Blood.

Expression of p53 protein in T- and natural killer-cell lymphomas is associated with some clinicopathologic entities but rarely related to p53 mutations.

P. Gaulard, M. Druet‐Cabanac, K. Leroy, 2001, Human pathology.

Survival effect of darbepoetin alfa in patients with diffuse large B-cell lymphoma (DLBCL) treated with immunochemotherapy: The LNH03-6B study.

T. Molina, B. Coiffier, H. Tilly, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

MR appearance of multiple myeloma of the spine before and after treatment.

A. Rahmouni, C. Haioun, F. Reyes, 1993, AJR. American journal of roentgenology.

Relapsed/Refractory International Prognostic Index (R/R‐IPI): An international prognostic calculator for relapsed/refractory diffuse large B‐cell lymphoma

M. Ziepert, N. Schmitz, G. Salles, 2021, American journal of hematology.

Autologous hematopoietic stem cell transplantation in intermediate and high grade non-Hodgkin's lymphoma: a review.

B. Coiffier, H. Tilly, C. Gisselbrecht, 1993, Annals of oncology : official journal of the European Society for Medical Oncology.

All aggressive lymphoma subtypes do not share similar outcome after front-line autotransplantation: a matched-control analysis by the Groupe d'Etude des Lymphomes de l'Adulte (GELA).

A. Stamatoullas, F. Morschhauser, P. Feugier, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

Helicobacter pylori and gastric lymphoma: high seroprevalence of CagA in diffuse large B-cell lymphoma but not in low-grade lymphoma of mucosa-associated lymphoid tissue type

C. Copie-Bergman, C. Haioun, L. Deforges, 2001, American Journal of Gastroenterology.

Long-term course of precancerous lesions arising in patients with gastric MALT lymphoma.

A. Amiot, I. Sobhani, C. Copie-Bergman, 2017, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Metachronous gastric MALT lymphoma and early gastric cancer: is residual lymphoma a risk factor for the development of gastric carcinoma?

C. Copie-Bergman, P. Gaulard, K. Leroy, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

Prognostic value of translocation t(11;18) in tumoral response of low-grade gastric lymphoma of mucosa-associated lymphoid tissue type to oral chemotherapy.

C. Copie-Bergman, P. Gaulard, K. Leroy, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Duodenal mucosa-associated lymphoid tissue lymphoma: treatment with oral cyclophosphamide

C. Copie-Bergman, C. Haioun, D. Lamarque, 2000, American Journal of Gastroenterology.

Duodenal mucosa-associated lymphoid tissue lymphoma: treatment with oral cyclophosphamide.

C. Copie-Bergman, C. Haioun, D. Lamarque, 2000 .

Endoscopic ultrasonography for the initial staging and follow-up in patients with low-grade gastric lymphoma of mucosa-associated lymphoid tissue treated medically.

C. Haioun, P. Hammel, D. Lamarque, 1997, Gastrointestinal endoscopy.

Chronic hepatitis C virus and gastric MALT lymphoma.

J. Pawlotsky, D. Dhumeaux, C. Haioun, 1998, Blood.

Efficacy of autologous stem cell transplantation in mantle cell lymphoma: a 3-year follow-up study

B. Quesnel, C. Gisselbrecht, N. Brousse, 2000, Bone Marrow Transplantation.

Prolonged Remissions After Nivolumab Plus Gemcitabine/Oxaliplatin in Relapsed/Refractory T-cell Lymphoma

A. Rosenwald, R. Houot, M. Ziepert, 2022, HemaSphere.

Whole exome sequencing of relapsed/refractory patients expands the repertoire of somatic mutations in diffuse large B‐cell lymphoma

C. Copie-Bergman, F. Jardin, G. Salles, 2016, Genes, chromosomes & cancer.

Minimal Change Nephrotic Syndrome Associated With Non-Hodgkin Lymphoid Disorders

C. Copie-Bergman, C. Haioun, A. Moktefi, 2014, Medicine.

Genome-Wide Association Study of Event-Free Survival in Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy.

J. Cerhan, T. Molina, F. Jardin, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic model for high-tumor-burden follicular lymphoma integrating baseline and end-induction PET: a LYSA/FIL study.

G. Salles, M. Federico, H. Tilly, 2018, Blood.

Expression of the Alpha/Beta and Gamma/ Delta T-cell Receptors in 57 Cases of Peripheral T-cell Lymphomas Identification of a Subset of y/6 T-ceII Lymphomas

P. Gaulard, C. Haioun, J. P. Couédic, 2007 .

Improvement of Early 18F-FDG PET Interpretation in Diffuse Large B-Cell Lymphoma: Importance of the Reference Background

M. Juweid, C. Haioun, M. Meignan, 2010, The Journal of Nuclear Medicine.

Interim 18F-fluorodeoxyglucose positron emission tomography in diffuse large B-cell lymphoma: qualitative or quantitative interpretation – where do we stand?

C. Haioun, A. Gallamini, M. Meignan, 2009, Leukemia & lymphoma.

Clinical impact of contrast-enhanced computed tomography (CECT) combined with low-dose FDG PET/CT on lymphoma patient management

A. Luciani, A. Rahmouni, C. Haioun, 2012 .

Report on the Second International Workshop on interim positron emission tomography in lymphoma held in Menton, France, 8–9 April 2010

C. Haioun, A. Gallamini, M. Meignan, 2010, Leukemia & lymphoma.

Significant Prognostic Impact of [18F]Fluorodeoxyglucose-PET Scan Performed During and At the End of Treatment with R-CHOP in High-Tumor Mass Follicular Lymphoma Patients: A GELA-GOELAMS Study

G. Salles, H. Tilly, N. Mounier, 2011 .

Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial

T. Molina, F. Jardin, G. Salles, 2011, The Lancet.

Report on the Third International Workshop on Interim Positron Emission Tomography in Lymphoma held in Menton, France, 26–27 September 2011 and Menton 2011 consensus

S. Barrington, C. Haioun, A. Gallamini, 2012, Leukemia & lymphoma.

lymphoma patients: results of the GELA-GOELAMS FL2000 study Rituximab combined with chemotherapy and interferon in follicular

J. Rossi, G. Salles, R. Bouabdallah, 2013 .

Pralatrexate is an effective treatment for relapsed or refractory transformed mycosis fungoides: a subgroup efficacy analysis from the PROPEL study.

B. Coiffier, C. Haioun, S. Horwitz, 2012, Clinical lymphoma, myeloma & leukemia.

A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: the EXPECT trial.

B. Coiffier, C. Haioun, J. Gabarre, 2013, European journal of cancer.

New insights into breast implant-associated anaplastic large cell lymphoma

P. Gaulard, P. Brousset, C. Haioun, 2018, Current opinion in oncology.

Successful Long‐Term Outcome of the First Combined Heart and Kidney Transplant in a Patient with Systemic AL Amyloidosis

L. Salomon, C. Haioun, P. Grimbert, 2008, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

Hepatitis C virus infection, mixed cryoglobulinemia, and B‐cell non‐Hodgkin's lymphoma

J. Pawlotsky, D. Dhumeaux, C. Haioun, 1999, Hepatology.

High-dose therapy followed by stem cell transplantation in partial response after first-line induction therapy for aggressive non-Hodgkin's lymphoma.

P. Gaulard, B. Coiffier, H. Tilly, 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

Long-term follow-up of high-dose treatment with autologous haematopoietic progenitor cell support in 693 patients with follicular lymphoma: an EBMT registry study

N. Schmitz, S. Montoto, T. A. Lister, 2007, Leukemia.

Long-term follow-up of lenalidomide in relapsed/refractory mantle cell lymphoma: subset analysis of the NHL-003 study

J. Vose, M. Czuczman, H. Tilly, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Obinutuzumab (GA101) monotherapy in relapsed/refractory diffuse large b-cell lymphoma or mantle-cell lymphoma: results from the phase II GAUGUIN study.

G. Salles, R. Bouabdallah, P. Feugier, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase III study of ACVBP versus ACVBP plus rituximab for patients with localized low-risk diffuse large B-cell lymphoma (LNH03-1B).

B. Coiffier, O. Casasnovas, H. Tilly, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d'Etude des Lymphomes de l'Adulte.

G. Salles, O. Casasnovas, H. Tilly, 2013, Blood.

study from the GELA patients with advanced follicular lymphoma: the GELF-94 randomized high-dose therapy with autologous stem cell transplantation in untreated Standard chemotherapy with interferon compared to CHOP followed by

G. Salles, B. Coiffier, R. Bouabdallah, 2013 .

Phase III study of ACVBP versus ACVBP plus rituximab for patients with localized low-risk diffuse large B-cell lymphoma ( LNH 03-1 B )

er, O. Casasnovas, H. Tilly, 2013 .

Rituximab induction immunotherapy for first-line low-tumor-burden follicular lymphoma: survival analyses with 7-year follow-up.

G. Salles, H. Tilly, N. Brousse, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial

T. Molina, F. Jardin, G. Salles, 2011, The Lancet.

CHOP and DHAP plus rituximab followed by autologous stem cell transplantation (ASCT) in mantle cell lymphoma (MCL): A pilot study from the GELA.

G. Salles, O. Casasnovas, H. Tilly, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

ZOHé: A Prospective Study of the Use of Biosimilar Filgrastim Zarzio in Clinical Practice in Patients Treated With Chemotherapy for Lymphoid Malignancies

C. Haioun, Isabelle Gasnereau, P. Solal-Céligny, 2017, Clinical lymphoma, myeloma & leukemia.

Polymerase chain reaction (PCR) amplification demonstrates the absence of human T-cell lymphotrophic virus (HTLV)-I specific pol sequences in peripheral T-cell lymphomas

P. Gaulard, C. Haioun, F. Reyes, 1990, Journal of Clinical Immunology.

transplantation in aggressive lymphomas Pregnancies after high-dose chemotherapy and autologous stem cell

C. Gisselbrecht, C. Haioun, M. André, 2012 .

Central nervous system relapse in patients over 80 years with diffuse large B‐cell lymphoma: an analysis of two LYSA studies

F. Jardin, P. Gaulard, H. Tilly, 2018, Cancer medicine.

Impact of doxorubicin dose capping on the outcome of DLBCL patients with elevated body surface area.

R. Houot, G. Salles, B. Coiffier, 2017, Blood.

Impact of rituximab on stem cell mobilization following ACVBP regimen in poor‐risk patients with diffuse large B‐cell lymphoma: results from a large cohort of patients

G. Salles, H. Tilly, N. Mounier, 2013, Transfusion.

Darbepoetin alfa administration in patients with non-Hodgkin lymphoma and chemotherapy-induced anemia receiving (±R)CHOP

C. Haioun, G. Verhoef, P. Lugtenburg, 2013, Hematology.

Anemia and erythropoiesis-stimulating agent administration in patients with non-Hodgkin lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisolone ± rituximab chemotherapy: results from an observational study

A. Salar, U. Jaeger, C. Haioun, 2011, Leukemia and Lymphoma.

Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large-B-cell lymphoma: influence of rituximab.

T. Molina, B. Coiffier, P. Feugier, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

Mediastinal Diffuse Large‐Cell Lymphoma with Sclerosis: A Condition with a Poor Prognosis

P. Gaulard, F. Roudot-thoraval, C. Haioun, 1989, American journal of clinical oncology.

Another look at follicular lymphoma: immunophenotypic and molecular analyses identify distinct follicular lymphoma subgroups

C. Copie-Bergman, M. Calaminici, M. Baia, 2013, Histopathology.

Folliculotropic T‐cell infiltrates associated with B‐cell chronic lymphocytic leukaemia or MALT lymphoma may reveal either true mycosis fungoides or pseudolymphomatous reaction: seven cases and review of the literature

C. Haioun, O. Chosidow, M. Beylot-Barry, 2015, Journal of the European Academy of Dermatology and Venereology : JEADV.

Colonic mucosa-associated lymphoid tissue lymphoma: a case series

A. Amiot, I. Sobhani, C. Copie-Bergman, 2019, Leukemia & lymphoma.

Cutaneous Tumor of the Arm Revealing a Sporadic Burkitt Lymphoma

C. Haioun, O. Chosidow, N. Ortonne, 2016, Journal of the American Geriatrics Society.

Histiocytoid Sweet Syndrome Is More Frequently Associated With Myelodysplastic Syndromes Than the Classical Neutrophilic Variant

C. Haioun, P. Wolkenstein, O. Chosidow, 2016, Medicine.

Peripheral T‐cell lymphoma presenting as predominant liver disease: A report of three cases

P. Gaulard, C. Haioun, E. Zafrani, 1986, Hepatology.

Brentuximab vedotin in refractory or relapsed peripheral T-cell lymphomas: the French named patient program experience in 56 patients

P. Gaulard, R. Bouabdallah, H. Tilly, 2016, Haematologica.

Prognostic Factors and Long Term Outcome of 138 Adults with Systemic Anaplastic Large-Cell Lymphoma: a Retrospective Study by the Groupe d'Etude Des Lymphomes De l'Adulte (GELA)

P. Gaulard, B. Coiffier, H. Tilly, 2010 .

Long-term follow-up of an age-adapted C5R protocol followed by radiotherapy in 99 newly diagnosed primary CNS lymphomas: a prospective multicentric phase II study of the Groupe d'Etude des Lymphomes de l'Adulte (GELA).

J. Blay, B. Coiffier, O. Casasnovas, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Incidence and risk factors of central nervous system relapse in histologically aggressive non-Hodgkin's lymphoma uniformly treated and receiving intrathecal central nervous system prophylaxis: A GELA study on 974 patients

H. Tilly, É. Lepage, C. Haioun, 2000 .

Current status and future perspectives for yttrium-90 (90Y)-ibritumomab tiuxetan in stem cell transplantation for non-Hodgkin's lymphoma

H. Tilly, C. Gisselbrecht, A. Nagler, 2007, Bone Marrow Transplantation.

Comparison of genetic probe with immunophenotype analysis in lymphoproliferative disorders: a study of 87 cases.

P. Gaulard, C. Haioun, M. Goossens, 1988, Blood.

Rituximab ( Anti-CD 20 Monoclonal Antibody ) for the Treatment of Patients With Relapsing or Refractory Aggressive Lymphoma : A Multicenter Phase II Study

V. Diehl, B. Coiffier, J. Radford, 1998 .

Intensive therapy with peripheral blood progenitor cell transplantation in 60 patients with poor-prognosis follicular lymphoma.

G. Salles, B. Coiffier, C. Gisselbrecht, 1995, Blood.

Polatuzumab Vedotin Combined with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) for Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results of a Phase Ib/II Study

G. Salles, K. Kolibaba, H. Tilly, 2016 .

Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: Final analysis of the GELA-GOELAMS FL2000 study with a 5-year follow-up

J. Rossi, G. Salles, R. Bouabdallah, 2007 .

Distinct germline genetic susceptibility profiles identified for common non-Hodgkin lymphoma subtypes

J. Cerhan, G. Colditz, E. Ziv, 2022, Leukemia.

Management and outcome of primary CNS lymphoma in the modern era: An LOC network study.

R. Houot, F. Jardin, K. Hoang-Xuan, 2020, Neurology.

Impact of rituximab and/or high-dose therapy with autotransplant at time of relapse in patients with follicular lymphoma: a GELA study.

B. Coiffier, P. Feugier, H. Tilly, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A multivariate analysis of the survival of patients with aggressive lymphoma: variations in the predictive value of prognostic factors during the course of the disease. Groupe d'Etudes des Lymphomes de l'Adulte.

B. Coiffier, H. Tilly, C. Gisselbrecht, 1998, Cancer.

R-CHOP14 compared to R-CHOP21 in elderly patients with diffuse large B-cell lymphoma (DLBCL): Final analysis of the LNH03-6B GELA study.

T. Molina, G. Salles, H. Tilly, 2012 .

Superiority of late over early intensification in relapsing/refractory aggressive non-Hodgkin's lymphoma: A randomized study from the GELA: LNH RP 93

G. Salles, B. Coiffier, H. Tilly, 1997 .

Presence of HTLV‐I proviral DNA in patients with adult T‐Cell leukemia/lymphoma in Taiwan

P. Gaulard, T. Henni, C. Haioun, 1988 .

Bone Marrow Involvement in Lymphomas With Hemophagocytic Syndrome at Presentation: A Clinicopathologic Study of 11 Patients in a Western Institution

C. Copie-Bergman, P. Gaulard, Y. Allory, 2001, The American journal of surgical pathology.

Peripheral T-cell Lymphomas With a Follicular Growth Pattern are Derived From Follicular Helper T Cells (TFH) and may Show Overlapping Features With Angioimmunoblastic T-cell Lymphomas

C. Copie-Bergman, P. Gaulard, T. Marafioti, 2009, The American journal of surgical pathology.

Rituximab in Combination with CHOP Regimen in Angioimmunoblastic T-Cell Lymphoma (AITL). Preliminary Results in 9 Patients Treated in a Single Institution.

P. Gaulard, A. Rahmouni, C. Haioun, 2005 .

Original Fludarabine alone compared to CHVP plus interferon in elderly patients with follicular lymphoma and adverse prognostic parameters: A GELA study

R. Bouabdallah, N. Brousse, C. Haioun, 2005 .

Hepatitis C virus infection in patients with overt B-cell non-Hodgkin's lymphoma in a French center.

P. Gaulard, J. Pawlotsky, D. Dhumeaux, 1999, Blood.

Immunoblastic lymphoma involving the bone marrow in a patient with alpha chain disease. Clinical and immunoelectron microscopic study

C. Haioun, F. Reyes, M. Tulliez, 1985, Cancer.

Flow Cytometric Immunophenotyping of Cerebrospinal Fluid

W. Wilson, A. Órfão, A. Porwit, 2008, Current protocols in cytometry.

Outcomes after ﬁ rst-line immunochemotherapy for primary mediastinal B-cell lymphoma: a LYSA study

R. Houot, F. Jardin, C. Haioun, 2021 .

Clinical and biological analysis of peripheral T-cell lymphomas: a single institution study.

P. Gaulard, F. Roudot-thoraval, C. Haioun, 1992, Leukemia & lymphoma.

Bone marrow histologic and immunohistochemical findings in peripheral. T-cell lymphoma: A study of 38 cases.

P. Gaulard, C. Haioun, F. Reyes, 1991, Human pathology.

Expression of the alpha beta and gamma delta T-cell receptors in peripheral T-cell lymphomas.

P. Gaulard, C. Haioun, F. Reyes, 1990, Nouvelle revue francaise d'hematologie.

High Response Rate After 4 Courses of R-DHAP In Untreated Mantle Cell Lymphoma (MCL) Patients In the Ongoing Phase III Randomized GOELAMS and GELA LyMa Trial

R. Houot, E. Macintyre, H. Tilly, 2010 .

Final Results of the IELSG-19 Randomized Trial of Mucosa-Associated Lymphoid Tissue Lymphoma: Improved Event-Free and Progression-Free Survival With Rituximab Plus Chlorambucil Versus Either Chlorambucil or Rituximab Monotherapy.

G. Salles, E. Campo, F. Cavalli, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I/II study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered weekly to patients (pts) with relapsed/refractory B-cell non-Hodgkin lymphoma (NHL).

R. Houot, C. Copie-Bergman, B. Coiffier, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Genome-wide association study identifies multiple susceptibility loci for diffuse large B-cell lymphoma

Paolo Vineis, Theodore R Holford, Peter Kraft, 2014, Nature Genetics.

Genetically predicted longer telomere length is associated with increased risk of B-cell lymphoma subtypes.

Paolo Vineis, Theodore R Holford, Peter Kraft, 2016, Human molecular genetics.

IL-12 Secreting Dendritic Cells are Required for Optimum Activation of Human Secondary Lymphoid Tissue T Cells

C. Copie-Bergman, C. Haioun, J. Farcet, 2002, Journal of immunotherapy.

Second cancers and late toxicities after treatment of aggressive non-Hodgkin lymphoma (NHL) with the ACVBP regimen. A GELA (Groupe d'Etude des Lymphomes de l'Adulte) cohort study on 2849 patients.

P. Gaulard, B. Coiffier, H. Tilly, 2001 .

Six-Year Results From RELEVANCE: Lenalidomide Plus Rituximab (R2) Versus Rituximab-Chemotherapy Followed by Rituximab Maintenance in Untreated Advanced Follicular Lymphoma

L. Sehn, I. Flinn, L. Xerri, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Single nucleotide polymorphisms in ABCB1 and CBR1 can predict toxicity to R-CHOP type regimens in patients with diffuse non-Hodgkin lymphoma

F. Jardin, G. Salles, H. Tilly, 2015, Haematologica.

Single nucleotide polymorphisms in ABCB 1 and CBR 1 can predict toxicity to R-CHOP type regimens in patients with diffuse non Hodgkin lymphoma by

F. Jardin, G. Salles, H. Tilly, 2015 .

Single Nucleotide Polymorphisms in ABCB1 and CBR1 Predict Toxicity to R-CHOP Type Regimens in Patients with Diffuse Non Hodgkin's Lymphoma

F. Jardin, G. Salles, H. Tilly, 2012 .

Lethal midline granuloma (polymorphic reticulosis) and lymphomatoid granulomatosis. Evidence for a monoclonal T-cell lymphoproliferative disorder.

P. Gaulard, C. Haioun, F. Reyes, 1988, Cancer.

The importance of G-CSF prophylaxis in R-CHOP-14 therapy for diffuse large B-cell lymphoma in routine clinical practice

A. Salar, U. Jaeger, C. Haioun, 2017 .

Second primary malignancies in patients treated for gastric mucosa-associated lymphoid tissue lymphoma

A. Amiot, I. Sobhani, C. Copie-Bergman, 2017, Leukemia & lymphoma.

Prognostic Value of Interim 18F-FDG PET in Patients with Diffuse Large B-Cell Lymphoma: SUV-Based Assessment at 4 Cycles of Chemotherapy

A. Rahmouni, C. Haioun, M. Meignan, 2009, Journal of Nuclear Medicine.

Rituximab exposure is influenced by baseline metabolic tumor volume and predicts outcome of DLBCL patients: a Lymphoma Study Association report.

G. Salles, O. Casasnovas, P. Feugier, 2017, Blood.

Immunoglobulin heavy chain/light chain pair measurement is associated with survival in diffuse large B-cell lymphoma

C. Copie-Bergman, T. Molina, F. Jardin, 2013, Leukemia & lymphoma.

Optimal oncologic management and mTOR inhibitor introduction are safe and improve survival in kidney and liver allograft recipients with de novo carcinoma

C. Tournigand, L. Salomon, A. De la taille, 2018, International journal of cancer.

Impact of [(18)F]fluorodeoxyglucose positron emission tomography response evaluation in patients with high-tumor burden follicular lymphoma treated with immunochemotherapy: a prospective study from the Groupe d'Etudes des Lymphomes de l'Adulte and GOELAMS.

G. Salles, L. Xerri, P. Feugier, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I study of IV aflibercept (Afl) in combination with R-CHOP in untreated patients (pts) with B-cell lymphoma.

F. Jardin, P. Gaulard, H. Tilly, 2010 .

Rituximab and chlorambucil versus rituximab alone in gastric mucosa-associated lymphoid tissue lymphoma according to t(11;18) status: a monocentric non-randomized observational study

A. Amiot, I. Sobhani, C. Copie-Bergman, 2013, Leukemia & lymphoma.

Treatment of t(11;18)-positive gastric mucosa-associated lymphoid tissue lymphoma with rituximab and chlorambucil: clinical, histological, and molecular follow-up

I. Sobhani, C. Copie-Bergman, P. Gaulard, 2010, Leukemia & lymphoma.

Long-term results of the GELA study comparing R-CHOP and CHOP chemotherapy in older patients with diffuse large B-cell lymphoma show good survival in poor-risk patients

B. Coiffier, P. Feugier, H. Tilly, 2007 .

Whole-Body Diffusion-weighted MR Imaging of Iron Deposits in Hodgkin, Follicular, and Diffuse Large B-Cell Lymphoma.

A. Luciani, C. Copie-Bergman, A. Rahmouni, 2017, Radiology.

A Phase II Open-Label, Multi-Center Study of Anti-CCR4 Monoclonal Antibody Mogamulizumab (KW-0761) in Patients with Previously Treated Peripheral T-Cell Lymphoma(PTCL)

B. Coiffier, F. d'Amore, J. Radford, 2014 .

SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma.

B. Coiffier, J. Jais, C. Haioun, 2011, Blood.

CNS prophylaxis in diffuse large B-cell lymphoma – Authors' reply

G. Salles, B. Coiffier, H. Tilly, 2012, The Lancet.

Recombinative events of the T cell antigen receptor delta gene in peripheral T cell lymphomas.

P. Gaulard, M. Lefranc, C. Haioun, 1991, The Journal of clinical investigation.

Report of the 6th International Workshop on PET in lymphoma

I. Buvat, W. Oyen, B. Cheson, 2017, Leukemia & lymphoma.

An international validation study of the prognostic role of interim FDG PET/CT in diffuse large B-cell lymphoma

B. Siegel, C. Haioun, A. Biggi, 2012 .

Early Response Evaluation with 18FDG-PET Scanning, but Not Phenotypic Profile, Are Predictive of Outcome in Diffuse Large B-Cell Lymphoma.

C. Copie-Bergman, P. Gaulard, A. Rahmouni, 2005 .

Characterization of CXCL13+ Neoplastic T Cells in Cutaneous Lesions of Angioimmunoblastic T-cell Lymphoma (AITL)

C. Copie-Bergman, P. Gaulard, C. Haioun, 2007, The American journal of surgical pathology.

Inhibition of Hedgehog signaling for the treatment of lymphoma and CLL: a phase II study from the LYSA.

R. Houot, G. Salles, K. Hoang-Xuan, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Frequent and Rapid Progression of Atrophy and Intestinal Metaplasia in Gastric Mucosa of Patients with MALT Lymphoma

F. Roudot-thoraval, C. Haioun, D. Lamarque, 2006, The American Journal of Gastroenterology.

A Prospective Randomized Study Comparing Dose Intensive Immunochemotherapy with R-ACVBP vs Standard R-CHOP In Younger Patients with Diffuse Large B-Cell Lymphoma (DLBCL). Groupe d'Etude Des Lymphomes De l'Adulte (GELA) Study LNH03-2B

T. Molina, F. Jardin, B. Coiffier, 2010 .

Surgical resection plus chemotherapy versus chemotherapy alone: comparison of two strategies to treat diffuse large B-cell gastric lymphoma.

É. Lepage, C. Haioun, A. Delmer, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

Obinutuzumab plus lenalidomide (GALEN) in advanced, previously untreated follicular lymphoma in need of systemic therapy.

R. Houot, G. Salles, R. Bouabdallah, 2021, Blood.

Primary thrombocythaemia associated with systemic mastocytosis: a report of five cases

P. Gaulard, J. Diebold, C. Haioun, 1991, British journal of haematology.

Association of primary pleural effusion lymphoma of T-cell origin and human herpesvirus 8 in a human immunodeficiency virus-seronegative man.

P. Gaulard, C. Haioun, M. Delfau-Larue, 2009, Archives of pathology & laboratory medicine.

lymphoproliferative disorders: a study of 87 cases Comparison of genetic probe with immunophenotype analysis in

P. Gaulard, C. Haioun, M. Goossens, 2011 .

Breast implant-associated anaplastic large cell lymphoma: two distinct clinicopathological variants with different outcomes.

P. Gaulard, P. Brousset, L. Xerri, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Follicular Peripheral T-cell Lymphoma Expands the Spectrum of Classical Hodgkin Lymphoma Mimics

C. Copie-Bergman, P. Gaulard, S. Swerdlow, 2012, The American journal of surgical pathology.

Expression of CXCL13 by Neoplastic Cells in Angioimmunoblastic T-Cell Lymphoma (AITL): A New Diagnostic Marker Providing Evidence That AITL Derives From Follicular Helper T Cells

C. Copie-Bergman, P. Gaulard, C. Haioun, 2006, The American journal of surgical pathology.

CD19 CAR T-Cell Therapy in Patients with Relapse/Refractory DLBCL: Retrospective Analysis of the Eligibility Criteria

P. Feugier, S. Chevret, C. Haioun, 2019, Blood.

Fatal splenic rupture after discontinuing treatment by ibrutinib and venetoclax in relapse/refractory mantle cell lymphoma

F. Lemonnier, C. Haioun, L. Roulin, 2021, Annals of Hematology.

Rituximab maintenance for 2-years significantly improves the outcome of patients with untreated high tumor burden follicular lymphoma after response to immunochemotherapy: results of the PRIMA study

A. Hagenbeek, G. Salles, A. López-Guillermo, 2010 .

Single Treatment with Rituximab Monotherapy for Low-Tumor Burden Follicular Lymphoma (FL): Survival Analyses with Extended Follow-Up (F/Up) of 7 Years.

G. Salles, H. Tilly, N. Brousse, 2006 .

Long Term Follow-up of the PRIMA Study: Half of Patients Receiving Rituximab Maintenance Remain Progression Free at 10 Years

G. Salles, A. López-Guillermo, B. Coiffier, 2017 .

Percutaneous Fine Needle Aspiration Cytology and Biopsy in the Diagnosis and Classification of Lymphoma: Clinical Evaluation.

P. Gaulard, C. Haioun, F. Reyes, 1991, Leukemia & lymphoma.

Expression of the alpha/beta and gamma/delta T-cell receptors in 57 cases of peripheral T-cell lymphomas. Identification of a subset of gamma/delta T-cell lymphomas.

P. Gaulard, C. Haioun, F. Reyes, 1990, The American journal of pathology.

Hepatosplenic T-cell lymphoma: sinusal/sinusoidal localization of malignant cells expressing the T-cell receptor gamma delta.

P. Gaulard, C. Haioun, M. Goossens, 1990, Blood.

Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial

R. Advani, J. Briones, G. Salles, 2019, The Lancet.

DIFFUSE LARGE B-CELL LYMPHOMA-ASSOCIATED-RETINOPATHY CHARACTERIZED BY MINIMAL MORPHOLOGIC CHANGES AND SEVERE FUNCTIONAL IMPAIRMENT.

E. Souied, C. Haioun, C. Thirkill, 2017 .

Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Groupe d'Etudes des Lymphomes de l'Adulte (GELA).

P. Gaulard, F. Berger, B. Coiffier, 1998, Blood.

des Lymphomes de l'Adulte (GELA) trials angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude Clinical, biologic, and pathologic features in 157 patients with

P. Gaulard, B. Coiffier, J. Diebold, 2013 .

Long-term outcome of adults with systemic anaplastic large-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte trials.

P. Gaulard, B. Coiffier, H. Tilly, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials.

P. Gaulard, B. Coiffier, J. Diebold, 2008, Blood.

Prognostic factors in patients with aggressive non-Hodgkin's lymphoma treated by front-line autotransplantation after complete remission: a cohort study by the Groupe d'Etude des Lymphomes de l'Adulte.

A. Stamatoullas, F. Morschhauser, P. Feugier, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A multivariate analysis of the survival of patients with aggressive lymphoma

B. Coiffier, H. Tilly, C. Gisselbrecht, 1998 .

Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin's lymphoma: updated results of the prospective study LNH87-2. Groupe d'Etude des Lymphomes de l'Adulte.

P. Gaulard, B. Coiffier, H. Tilly, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

CD5-CD56+ T-cell receptor silent peripheral T-cell lymphomas are natural killer cell lymphomas.

P. Gaulard, T. Petrella, C. Haioun, 1996, Blood.

Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma. Groupe d'Etude des Lymphomes de l'Adulte (GELA).

J Diebold, P. Gaulard, G. Salles, 1996, Blood.

lymphomas Prognostic significance of survivin expression in diffuse large B-cell

T. Molina, P. Gaulard, G. Salles, 2013 .

Efficacy of single-agent chemotherapy in low-grade B-cell mucosa-associated lymphoid tissue lymphoma with prominent gastric expression.

P. Gaulard, C. Haioun, F. Reyes, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts

Salles, K. Tarte, F. Jardin, 2018 .

Interleukin 4-induced gene 1 is activated in primary mediastinal large B-cell lymphoma.

C. Copie-Bergman, P. Gaulard, M. Dyer, 2003, Blood.

Interleukin 4 -induced gene 1 ( FIG1 ) is activated in primary mediastinal large B cell lymphoma Short running head : FIG1 gene activation in PMBL

P. Gaulard, P. Romeo, K. Leroy, 2002 .

Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study.

K. Savage, B. Coiffier, C. Gisselbrecht, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Expression of TFH Markers and Detection of RHOA p.G17V and IDH2 p.R172K/S Mutations in Cutaneous Localizations of Angioimmunoblastic T-Cell Lymphomas

C. Copie-Bergman, P. Gaulard, C. Haioun, 2017, The American journal of surgical pathology.

The IDH2 R172K mutation associated with angioimmunoblastic T-cell lymphoma produces 2HG in T cells and impacts lymphoid development

P. Gaulard, S. Inoue, T. Mak, 2016, Proceedings of the National Academy of Sciences.

EZH2 alterations in follicular lymphoma: biological and clinical correlations

F. Jardin, L. Xerri, S. Boyault, 2017, Blood Cancer Journal.

EZH2 alterations in follicular lymphoma: biological and clinical correlations

F. Jardin, G. Salles, L. Xerri, 2017, Blood Cancer Journal.

Low grade B cell mucosa associated lymphoid tissue lymphoma of the stomach: clinical and endoscopic features, treatment, and outcome.

P. Gaulard, C. Haioun, F. Reyes, 1992, Gut.

Activating mutations in genes related to TCR signaling in angioimmunoblastic and other follicular helper T-cell-derived lymphomas.

Ryan D. Morin, R. Gascoyne, P. Gaulard, 2016, Blood.

The alternative RelB NF-κB subunit is a novel critical player in diffuse large B-cell lymphoma.

C. Copie-Bergman, T. Molina, F. Jardin, 2021, Blood.

Lenalidomide Maintenance Compared With Placebo in Responding Elderly Patients With Diffuse Large B-Cell Lymphoma Treated With First-Line Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone.

R. Greil, P. Gaulard, G. Salles, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study.

C. Copie-Bergman, M. Baia, T. Molina, 2015, Blood.

An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma.

J. Vose, M. Czuczman, R. Bouabdallah, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Diffuse large B-cell lymphomas with CDKN2A deletion have a distinct gene expression signature and a poor prognosis under R-CHOP treatment: a GELA study.

T. Molina, F. Jardin, G. Salles, 2010, Blood.

High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial

K. Tarte, D. Maucort-Boulch, T. Fest, 2014, Leukemia.

Prognostic significance of received relative dose intensity in non-Hodgkin's lymphoma patients: application to LNH-87 protocol. The GELA. (Groupe d'Etude des Lymphomes de l'Adulte).

C Sebban, B. Coiffier, H. Tilly, 1993, Annals of oncology : official journal of the European Society for Medical Oncology.

Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study.

V. Diehl, B. Coiffier, J. Radford, 1998, Blood.

Refining diffuse large B-cell lymphoma subgroups using integrated analysis of molecular profiles

C. Copie-Bergman, T. Molina, F. Jardin, 2019, EBioMedicine.

l'Adulte (GELA) non- Hodgkin's lymphoma. Groupe d'Etude des Lymphomes de Prognostic significance of bcl-2 protein expression in aggressive

P. Gaulard, G. Salles, J. Diebold, 2002 .

Prognostic Significance of bcl-2 Protein Expression in Aggressive Non-Hodgkin's Lymphoma

P. Gaulard, G. Salles, J. Diebold, 1996 .

Aggressive lymphomas with renal involvement: a study of 48 patients treated with the LNH-84 and LNH-87 regimens. Groupe d'Etude des Lymphomes de l'Adulte.

H. Tilly, A. Delannoy, C. Haioun, 1994, British Journal of Cancer.

Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network

W. Klapper, E. Hoster, G. Salles, 2016, The Lancet.

Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial.

F. Jardin, P. Gaulard, B. Coiffier, 2011, The Lancet. Oncology.

Diffuse large B-cell lymphoma of Waldeyer's ring has distinct clinicopathologic features: a GELA study.

C. Copie-Bergman, M. Baia, T. Molina, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma.

L. Staudt, A. Rosenwald, W. Chan, 2019, Blood.

Integrative clinicopathological and molecular analyses of angioimmunoblastic T-cell lymphoma and other nodal lymphomas of follicular helper T-cell origin

P. Gaulard, M. Delorenzi, J. Jais, 2017, Haematologica.

Angioimmunoblastic T-cell lymphoma is the most common T-cell lymphoma in two distinct French information data sets

T. Molina, P. Gaulard, F. Berger, 2015, Haematologica.

Comparison of autologous bone marrow transplantation with sequential chemotherapy for intermediate-grade and high-grade non-Hodgkin's lymphoma in first complete remission: a study of 464 patients. Groupe d'Etude des Lymphomes de l'Adulte.

B. Coiffier, H. Tilly, C. Gisselbrecht, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Next-Generation Sequencing in Diffuse Large B-Cell Lymphoma Highlights Molecular Divergence and Therapeutic Opportunities: a LYSA Study

C. Copie-Bergman, T. Molina, F. Jardin, 2016, Clinical Cancer Research.

Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: the GELF-94 randomized study from the Groupe d'Etude des Lymphomes de l'Adulte (GELA).

G. Salles, B. Coiffier, R. Bouabdallah, 2006, Blood.

Total metabolic tumor volume, circulating tumor cells, cell-free DNA: distinct prognostic value in follicular lymphoma.

C. Copie-Bergman, J. Jais, C. Haioun, 2018, Blood advances.

Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma

G. Salles, L. Sehn, A. López-Guillermo, 2018, The New England journal of medicine.

Efficacy and toxicity of 2 schedules of frontline rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone plus bortezomib in patients with B‐cell lymphoma

G. Salles, C. Gisselbrecht, N. Mounier, 2009, Cancer.

Efficiency of in vivo purging with rituximab prior to autologous peripheral blood progenitor cell transplantation in B-cell non-Hodgkin's lymphoma: a single institution study.

P. Gaulard, C. Haioun, F. Reyes, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma.

W. Klapper, F. Jardin, E. Hoster, 2015, Blood.

Analysis of the intraclonal diversity of HLA‐A0201‐restricted T lymphocyte epitopes in follicular lymphoma idiotype

P. Gaulard, C. Haioun, J. Farcet, 2005, British journal of haematology.

Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol--a groupe d'Etude des lymphomes de l'Adulte study.

P. Gaulard, G. Salles, B. Coiffier, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Placebo-controlled phase III study of lenograstim (glycosylated recombinant human granulocyte colony-stimulating factor) in aggressive non-Hodgkin's lymphoma: factors influencing chemotherapy administration. Groupe d'Etude des Lymphomes de l'Adulte.

B. Coiffier, H. Tilly, C. Gisselbrecht, 1997, Leukemia & lymphoma.

A phase II, single‐arm, multicentre study of coltuximab ravtansine (SAR3419) and rituximab in patients with relapsed or refractory diffuse large B‐cell lymphoma

R. Houot, B. Coiffier, R. Bouabdallah, 2016, British journal of haematology.

Sinusoidal obstruction syndrome: a warning about autologous stem cell transplantation preceded by regimens containing oxaliplatin

J. Calderaro, C. Haioun, J. Tamburini, 2020, Bone Marrow Transplantation.

P. Gaffney, J. Cerhan, T. Molina, 2017, Lupus Science & Medicine.

Gene Expression Profile Analysis According to Recurrent Gene Copy Number Abnormalities Defines a Diffuse Large B-Cell Lymphoma Subgroup Characterized by 9p21 Locus Deletion, Ribosome Machinery Deregulation and Poor Prognosis. A GELA Study

T. Molina, F. Jardin, G. Salles, 2008 .

Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study.

L. Staudt, A. Rosenwald, W. Chan, 2006, Blood.

Structural profiles of TP 53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma : an international collaborative study

L. Staudt, A. Rosenwald, W. Chan, 2008 .

Impact of Expert Pathologic Review of Lymphoma Diagnosis: Study of Patients From the French Lymphopath Network.

Thomas Filleron, Jean-François Michiels, Peggy Dartigues, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[Leg ulcer associated with type I cryoglobulinaemia due to incipient B-cell lymphoma].

C. Copie-Bergman, P. Gaulard, C. Haioun, 2013, Annales de dermatologie et de venereologie.

Gene alterations in epigenetic modifiers and JAK-STAT signaling are frequent in breast implant-associated ALCL.

P. Gaulard, R. Bouabdallah, P. Brousset, 2019, Blood.

Rituximab after Autologous Stem‐Cell Transplantation in Mantle‐Cell Lymphoma

R. Houot, F. Jardin, G. Salles, 2017, The New England journal of medicine.

Rituximab plus gemcitabine and oxaliplatin in patients with refractory/relapsed diffuse large B-cell lymphoma who are not candidates for high-dose therapy. A phase II Lymphoma Study Association trial

P. Gaulard, G. Salles, A. Rahmouni, 2013, Haematologica.

Treatment with 5-azacytidine induces a sustained response in patients with angioimmunoblastic T-cell lymphoma.

P. Gaulard, F. Lemonnier, C. Haioun, 2018, Blood.

Long-term follow-up of patients with newly diagnosed follicular lymphoma in the prerituximab era: effect of response quality on survival--A study from the groupe d'etude des lymphomes de l'adulte.

G. Salles, B. Coiffier, H. Tilly, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Immuno-fluorescence in situ hybridization index predicts survival in patients with diffuse large B-cell lymphoma treated with R-CHOP: a GELA study.

C. Copie-Bergman, M. Baia, T. Molina, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial.

Catherine Thieblemont, Nicolas Mounier, Richard Delarue, 2013, The Lancet. Oncology.

[Intravascular large cell lymphoma revealed by diffuse telangiectasia and cauda equina syndrome].

C. Haioun, C. Badoual, F. Authier, 2002, Annales de dermatologie et de venereologie.

Recombinant interferon alfa-2b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma. Groupe d'Etude des Lymphomes de l'Adulte.

B. Coiffier, C. Gisselbrecht, N. Brousse, 1993, The New England journal of medicine.

Baseline 18F-FDG Metabolic Tumor Volume Predicts Response to Rituximab Induction in Post-transplant Lymphoproliferative Disorders: A Multi-institutional Retrospective Study

S. Leprêtre, P. Payoux, C. Haioun, 2023, HemaSphere.

Rituximab plus gemcitabine and oxaliplatin (R-GemOx) in refractory/relapsed diffuse large B-cell lymphoma: a real-life study in patients ineligible for autologous stem-cell transplantation

F. Jardin, P. Gaulard, H. Tilly, 2021, Leukemia & lymphoma.

FDG-PET-driven consolidation strategy in diffuse large B-cell lymphoma: final results of a randomized phase 2 study.

J. Jais, P. Feugier, H. Tilly, 2017, Blood.

Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy.

J. Cerhan, G. Salles, T. Habermann, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Accurate Classification of Germinal Center B-Cell-Like/Activated B-Cell-Like Diffuse Large B-Cell Lymphoma Using a Simple and Rapid Reverse Transcriptase-Multiplex Ligation-Dependent Probe Amplification Assay: A CALYM Study.

T. Molina, F. Jardin, G. Salles, 2015, The Journal of molecular diagnostics : JMD.

Final results of a randomized phase II GELA/LYSA study of rituximab plus ACVBP or CHOP, using a PET-driven consolidation strategy, in patients with high-risk diffuse large B-cell lymphoma (DLBCL).

T. Molina, B. Coiffier, J. Jais, 2014 .

Survival impact of rituximab combined with ACVBP and upfront consolidation autotransplantation in high-risk diffuse large B-cell lymphoma for GELA

G. Salles, O. Casasnovas, P. Feugier, 2011, Haematologica.

Prognostic value of PET-CT after first-line therapy in patients with follicular lymphoma: a pooled analysis of central scan review in three multicentre studies.

Annibale Versari, Michel Meignan, Fabien Ricard, 2014, The Lancet. Haematology.

The expression of 16 genes related to the cell of origin and immune response predicts survival in elderly patients with diffuse large B-cell lymphoma treated with CHOP and rituximab

T. Molina, P. Gaulard, G. Salles, 2008, Leukemia.

Respective prognostic values of germinal center phenotype and early (18)fluorodeoxyglucose-positron emission tomography scanning in previously untreated patients with diffuse large B-cell lymphoma.

C. Copie-Bergman, P. Gaulard, A. Rahmouni, 2007, Haematologica.

[18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome.

Emmanuel Itti, Michel Meignan, Felix Reyes, 2005, Blood.

Small lymphocytic lymphoma, marginal zone B-cell lymphoma, and mantle cell lymphoma exhibit distinct gene-expression profiles allowing molecular diagnosis.

P. Gaulard, G. Salles, F. Berger, 2004, Blood.

A gene-expression profiling score for outcome prediction disease in patients with follicular lymphoma: a retrospective analysis on three international cohorts

J. Cerhan, K. Tarte, F. Jardin, 2018, The Lancet. Oncology.

Baseline Metabolic Tumor Volume Predicts Outcome in High-Tumor-Burden Follicular Lymphoma: A Pooled Analysis of Three Multicenter Studies.

G. Salles, M. Federico, H. Tilly, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

PET/CT before autologous stem cell transplantation predicts outcome in refractory/relapsed follicular lymphoma

S. Mareschal, H. Tilly, C. Haioun, 2015, European Journal of Nuclear Medicine and Molecular Imaging.

Phase 1b study of lenalidomide in combination with rituximab-CHOP (R2-CHOP) in patients with B-cell lymphoma

T. Molina, F. Jardin, G. Salles, 2013, Leukemia.

A 4-weekly course of rituximab is safe and improves tumor control for patients with minimal residual disease persisting 3 months after autologous hematopoietic stem-cell transplantation: results of a prospective multicenter phase II study in patients with follicular lymphoma.

J. Rossi, G. Salles, G. Delsol, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

BCL2 expression but not MYC and BCL2 coexpression predicts survival in elderly patients with diffuse large B-cell lymphoma independently of cell of origin in the phase 3 LNH03-6B trial

C. Copie-Bergman, T. Molina, F. Jardin, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Pretherapy metabolic tumour volume is an independent predictor of outcome in patients with diffuse large B-cell lymphoma

H. Tilly, B. Siegel, C. Haioun, 2014, European Journal of Nuclear Medicine and Molecular Imaging.

Rituximab or rituximab plus chlorambucil for translocation (11;18)-negative gastric mucosa-associated lymphoid tissue lymphoma: a monocentric non-randomized observational study

A. Amiot, I. Sobhani, C. Haioun, 2022, Leukemia & lymphoma.

Effectiveness and Safety of Subcutaneous Rituximab for Patients With Gastric MALT Lymphoma: A Case-Control Comparison With Intravenous Rituximab.

A. Amiot, I. Sobhani, C. Copie-Bergman, 2020, Clinical lymphoma, myeloma & leukemia.

H. Tilly, É. Lepage, C. Haioun, 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

Obinutuzumab plus Lenalidomide (GALEN) for the treatment of relapse/refractory aggressive lymphoma: a phase II LYSA study

R. Houot, G. Salles, P. Feugier, 2018, Leukemia.

Role of up-front autologous stem-cell transplantation in peripheral T-cell lymphoma for patients in response after induction: an analysis of patients from LYSA centers

P. Gaulard, G. Salles, R. Bouabdallah, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Peripheral blood natural killer cell count is associated with clinical outcome in patients with aaIPI 2-3 diffuse large B-cell lymphoma.

G. Salles, J. Jais, O. Casasnovas, 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

Tandem autotransplant as first-line consolidative treatment in poor-risk aggressive lymphoma: a pilot study of 36 patients.

P. Gaulard, B. Quesnel, C. Gisselbrecht, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

Long-term follow-up of high-dose treatment (HDT) with autologous haematopoietic progenitor cell support in 702 patients (pts.) with follicular lymphoma (FL). An EBMT registry study.

N. Schmitz, S. Montoto, A. Rohatiner, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Fatigue level changes with time in long-term Hodgkin and non-Hodgkin lymphoma survivors: a joint EORTC-LYSA cross-sectional study

A. Stamatoullas, H. Tilly, H. Kluin-Nelemans, 2019, Health and Quality of Life Outcomes.

Report on the 5th International Workshop on Positron Emission Tomography in Lymphoma held in Menton, France, 19–20 September 2014

S. Barrington, C. Haioun, A. Gallamini, 2015, Leukemia & lymphoma.

The novel immunosuppressive enzyme IL4I1 is expressed by neoplastic cells of several B-cell lymphomas and by tumor-associated macrophages

C. Copie-Bergman, M. Baia, P. Gaulard, 2009, Leukemia.

Whole-Body Diffusion-weighted Imaging in Hodgkin Lymphoma and Diffuse Large B-Cell Lymphoma.

A. Luciani, A. Rahmouni, C. Haioun, 2015, Radiographics : a review publication of the Radiological Society of North America, Inc.

RCHOP and RDHAP Followed by Autologous Stem Cell Transplantation (ASCT) in Mantle Cell Lymphoma (MCL) : Final Results of a Phase II Study from the GELA

G. Salles, O. Casasnovas, H. Tilly, 2008 .

Biological and Clinical Relevance of Associated Genomic Alterations in MYD88 L265P and non-L265P–Mutated Diffuse Large B-Cell Lymphoma: Analysis of 361 Cases

C. Copie-Bergman, T. Molina, F. Jardin, 2016, Clinical Cancer Research.

Determination of Molecular Subtypes of Diffuse Large B-Cell Lymphoma Using a Reverse Transcriptase Multiplex Ligation-Dependent Probe Amplification Classifier: A CALYM Study.

T. Molina, F. Jardin, G. Salles, 2017, The Journal of molecular diagnostics : JMD.

Secondary Pancreatic Involvement by Diffuse Large B-Cell Lymphoma Presenting as Acute Pancreatitis: Treatment and Outcome

L. Tsakiris, C. Haioun, J. Delchier, 2011, Pancreatology.

Primary bone diffuse large B-cell lymphoma: a retrospective evaluation on 76 cases from French institutional and LYSA studies

D. Biau, G. Salles, H. Tilly, 2016, Leukemia & lymphoma.

Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) enrolled on randomized clinical trials

M. Ziepert, N. Schmitz, C. Flowers, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Outcomes of older patients with diffuse large B-cell lymphoma treated with R-CHOP: 10-year follow-up of the LNH03-6B trial

T. Molina, O. Casasnovas, P. Feugier, 2022, Blood advances.

Development of a Questionnaire for the Search for Occupational Causes in Patients with Non-Hodgkin Lymphoma: The RHELYPRO Study

R. Garnier, C. Haioun, Y. Esquirol, 2021, International journal of environmental research and public health.

A French multicentric prospective prognostic cohort with epidemiological, clinical, biological and treatment information to improve knowledge on lymphoma patients: study protocol of the “REal world dAta in LYmphoma and survival in adults” (REALYSA) cohort

G. Salles, C. Haioun, L. Fornecker, 2021, BMC Public Health.

Rituximab Maintenance Versus Wait and Watch after Four Courses of R-DHAP Followed By Autologous Stem Cell transplantation in Previously Untreated Young Patients with Mantle Cell Lymphoma: First Interim Analysis of the Phase III Prospective Lyma Trial, a Lysa Study

G. Salles, O. Casasnovas, H. Tilly, 2014 .

Phase II trial and prediction of response of single agent tipifarnib in patients with relapsed/refractory mantle cell lymphoma: a Groupe d’Etude des Lymphomes de l’Adulte trial

F. Jardin, R. Bouabdallah, R. Houlgatte, 2010, Cancer Chemotherapy and Pharmacology.

FCGR3A/2A polymorphisms and diffuse large B‐cell lymphoma outcome treated with immunochemotherapy: a meta‐analysis on 1134 patients from two prospective cohorts

J. Cerhan, T. Molina, G. Salles, 2017, Hematological oncology.

POLARGO: A Randomized Phase III Study Evaluating Polatuzumab Vedotin Plus Rituximab, Gemcitabine, and Oxaliplatin in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Who Had Received One or More Previous Therapies

J. Sancho, C. Haioun, M. Matasar, 2019, Blood.

International prognostic indices in diffuse large B-cell lymphoma (DLBCL): a comparison of IPI, R-IPI and NCCN-IPI.

M. Ziepert, N. Schmitz, G. Salles, 2020, Blood.

Fludarabine alone compared to CHVP plus interferon in elderly patients with follicular lymphoma and adverse prognostic parameters: a GELA study. Groupe d'Etudes des Lymphomes de l'Adulte.

B. Coiffier, R. Bouabdallah, H. Tilly, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

Quality of life-adjusted survival analysis of high-dose therapy with autologous bone marrow transplantation versus sequential chemotherapy for patients with aggressive lymphoma in first complete remission. Groupe d'Etude les Lymphomes de l'Adulte (GELA).

C Sebban, G. Salles, R. Bouabdallah, 2000, Blood.

Diagnosis-to-Treatment Interval Is an Important Clinical Factor in Newly Diagnosed Diffuse Large B-Cell Lymphoma and Has Implication for Bias in Clinical Trials.

J. Cerhan, T. Molina, G. Salles, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Personalized risk prediction for event‐free survival at 24 months in patients with diffuse large B‐cell lymphoma

J. Cerhan, R. Gascoyne, C. Copie-Bergman, 2016, American journal of hematology.

Autologous stem-cell transplantation as consolidation therapy for diffuse large B-cell lymphoma patients with overexpression of bcl-2 protein. Results of the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trial LNH98-B2.

P. Gaulard, G. Salles, M. Copin, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Combining gene expression profiling and machine learning to diagnose B-cell non-Hodgkin lymphoma

C. Copie-Bergman, T. Molina, F. Jardin, 2020, Blood Cancer Journal.

Rituximab in combination with CHOP regimen in angioimmunoblastic T-cell lymphoma: Results of the phase II RAIL trial--A prospective study of the Groupe d'Etude des Lymphomes de l'Adulte (GELA).

P. Gaulard, O. Casasnovas, C. Gisselbrecht, 2010 .

Compliance with ASCO 2006 recommendations for the use of "white blood cell growth factors" in advanced lung cancer (LC) or breast cancer (BC) or non-Hodgkin lymphoma (NHL): An interim analysis of French National Observational Study—The ZOHé study.

C. Haioun, P. Solal-Céligny, H. Roché, 2014 .

Immunohistochemistry as a valuable tool to assess CD30 expression in peripheral T-cell lymphomas: high correlation with mRNA levels.

P. Gaulard, M. Delorenzi, L. de Leval, 2014, Blood.

Real Time Pathological and Molecular Characterization of Aggressive B-Cell Lymphomas Based on a National Network. a Lysa Project

T. Molina, F. Jardin, G. Salles, 2020 .

R-ACVBP Benefits to Younger Patients with Non-Germinal Centre Diffuse Large B-Cell Lymphoma As Compared to R-CHOP in the GELA Trial LNH03-2B

C. Copie-Bergman, T. Molina, F. Jardin, 2011 .

Intravoxel Incoherent Motion Diffusion-weighted Imaging of Multiple Myeloma Lesions: Correlation with Whole-Body Dynamic Contrast Agent-enhanced MR Imaging.

A. Luciani, A. Rahmouni, C. Cuénod, 2015, Radiology.

Multiple myeloma treatment response assessment with whole-body dynamic contrast-enhanced MR imaging.

A. Luciani, A. Rahmouni, J. Deux, 2010, Radiology.

Efficacy and toxicity of two schedules of R-CHOP plus bortezomib in front-line B lymphoma patients: A randomized phase II trial from the Groupe d'Etude des Lymphomes de l'Adulte (GELA)

G. Salles, C. Gisselbrecht, N. Mounier, 2007 .

Quality of life in 269 patients with poor-risk diffuse large B-cell lymphoma treated with rituximab versus observation after autologous stem cell transplant

B. Coiffier, P. Feugier, H. Tilly, 2011, Leukemia & lymphoma.

Rituximab Combined to ACVBP (R-ACVBP) Supported by Pegfilgrastim as a New Inductive Treatment Followed by High-Dose Consolidative Autotransplantation (HDC) for Poor Risk Diffuse Large B-Cell Lymphoma (DLBCL) in First-Line. Results of LNH 03–39B. A GELA Study.

B. Coiffier, J. Jais, O. Casasnovas, 2007 .

Clinical relevance of flow cytometric immunophenotyping of the cerebrospinal fluid in patients with diffuse large B-cell lymphoma.

C. Copie-Bergman, P. Brugières, C. Haioun, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Subcutaneous Rituximab-MiniCHOP Compared With Subcutaneous Rituximab-MiniCHOP Plus Lenalidomide in Diffuse Large B-Cell Lymphoma for Patients Age 80 Years or Older.

F. Jardin, G. Salles, P. Feugier, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Survival Impact of Rituximab Combined to ACVBP (R-ACVBP) in 209 Poor Risk Diffuse Large B-Cell Lymphoma (DLBCL) Patients Treated with Upfront High-Dose Consolidative Autotransplantation (HDC) : A GELA Phase II Study

B. Coiffier, O. Casasnovas, P. Feugier, 2008 .

Deep-Learning Assessed Muscular Hypodensity Independently Predicts Mortality in DLBCL Patients Younger Than 60 Years

P. Feugier, H. Tilly, C. Haioun, 2021, Cancers.

The MAL gene is expressed in primary mediastinal large B-cell lymphoma.

C. Copie-Bergman, P. Gaulard, P. Romeo, 1999, Blood.

High-Dose Cytarabine and Autologous Stem-Cell Transplantation in Mantle Cell Lymphoma: Long-Term Follow-Up of the Randomized Mantle Cell Lymphoma Younger Trial of the European Mantle Cell Lymphoma Network

W. Klapper, E. Hoster, W. Hiddemann, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

MYC Gene Simple Hit Is a Strong Independent Predictive Factor of Survival in Diffuse Large B-Cell Lymphomas in Contrast to MYC Double-Hit Gene Alterations: A Study by the Groupe d'Etude Des Lymphomes De l'Adulte

C. Copie-Bergman, M. Baia, T. Molina, 2012 .

Quality of life of survivors 1 year after the diagnosis of diffuse large B-cell lymphoma: a LYSA study

F. Jardin, N. Mounier, C. Haioun, 2021, Annals of Hematology.

Economic burden in non‐Hodgkin lymphoma survivors: The French Lymphoma Study Association SIMONAL cross‐sectional study

G. Salles, J. Jais, P. Feugier, 2021, Cancer.

Long‐term fatigue in survivors of non‐Hodgkin lymphoma: The Lymphoma Study Association SIMONAL cross‐sectional study

G. Salles, J. Jais, P. Feugier, 2019, Cancer.

Pre-Phase Chemotherapy Followed By Ofatumumab (OFA) and Reduced Dose CHOP (OFA-mini-CHOP) for Patients over 80 Years with Diffuse Large B-Cell Lymphoma (DLBCL) – a Lymphoma Study Association (LYSA) Prospective Phase II Study (LNH09-7B)

F. Jardin, B. Coiffier, H. Tilly, 2014 .

Glofitamab As Monotherapy and in Combination with Obinutuzumab Induces High Complete Response Rates in Patients (pts) with Multiple Relapsed or Refractory (R/R) Follicular Lymphoma (FL)

R. Houot, C. Haioun, T. Phillips, 2021, Blood.

Prognostic value of PET-CT after frontline therapy in follicular lymphoma: A pooled analysis of central review in three multicenter studies.

G. Salles, L. Guerra, M. Federico, 2014 .

Rituximab Maintenance after Autologous Stem Cell Transplantation Prolongs Survival in Younger Patients with Mantle Cell Lymphoma: Final Results of the Randomized Phase 3 LyMa Trial of the Lysa/Goelams Group

G. Salles, O. Casasnovas, P. Feugier, 2016 .

Safety and efficacy of temsirolimus in combination with three different immuno-chemotherapy regimens in relapse and refractory mantle cell lymphoma, final results of the T3 phase IB trial of the LYSA

O. Casasnovas, C. Haioun, R. Gressin, 2020, Annals of Hematology.

Efficacy and toxicity of two schedules of bortezomib in patients with recurrent or refractory follicular lymphoma: a randomised phase II trial from the Groupe d'Etude des Lymphomes de l'Adulte (GELA).

B. Coiffier, R. Bouabdallah, O. Casasnovas, 2013, European journal of cancer.

The need for improved neutropenia risk assessment in DLBCL patients receiving R-CHOP-21: findings from clinical practice.

A. Salar, U. Jaeger, H. Johnsen, 2012, Leukemia research.

Interim [18F]fluorodeoxyglucose positron emission tomography scan in diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy plus rituximab.

C. Copie-Bergman, F. Jardin, A. Rahmouni, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Lenalidomide maintenance fails to overcome the unfavourable prognosis of low NK‐cell counts in rituximab–chemotherapy responsive elderly DLBCL patients: A LYSA group study

P. Gaulard, G. Salles, J. Jais, 2023, British journal of haematology.

Validation of the PRIMA-Prognostic Index for Patients Treated with Rituximab Plus Chemotherapy and Refinement of Prognostic Parameters for Patients on Rituximab Plus Lenalidomide in the Phase III Relevance Trial

G. Salles, L. Sehn, A. López-Guillermo, 2019, Blood.

Incidence of central nervous system relapses in patients with DLBCL treated with lenalidomide as maintenance after R-CHOP.

R. Greil, C. Copie-Bergman, P. Feugier, 2021, Blood advances.

Combination of ofatumumab and reduced-dose CHOP for diffuse large B-cell lymphomas in patients aged 80 years or older: an open-label, multicentre, single-arm, phase 2 trial from the LYSA group.

F. Jardin, B. Coiffier, H. Tilly, 2017, The Lancet. Haematology.

Preliminary results of a phase II study of rituximab (R), gemcitabine (Gem), oxaliplatin (Ox) plus enzastaurin (ENZ) followed by ENZ maintenance as salvage regimen for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

C. Haioun, F. Morschhauser, G. Hess, 2010 .

Rituximab vs Observation after High-Dose Consolidative First-Line Chemotherapy (HDC) with Autologous Stem Cell Transplantation in Poor Risk Diffuse Large B-Cell Lymphoma. Final Analysis of the LNH98-B3 GELA Study.

B. Coiffier, P. Feugier, H. Tilly, 2005 .

Germinal Center Phenotype Determined by Immunohistochemistry on Tissue Microarray Does Not Correlate with Outcome in Diffuse Large B-Cell Lymphoma Patients Treated with Immunochemotherapy in the Randomized Trial LNH98-5. A GELA Study.

T. Molina, P. Gaulard, G. Salles, 2007 .

Multiple Ways to Detect IDH2 Mutations in Angioimmunoblastic T-Cell Lymphoma from Immunohistochemistry to Next-Generation Sequencing.

C. Copie-Bergman, P. Gaulard, F. Lemonnier, 2018, The Journal of molecular diagnostics : JMD.

Long-term outcomes of adults with first-relapsed/refractory systemic anaplastic large-cell lymphoma in the pre-brentuximab vedotin era: A LYSA/SFGM-TC study.

P. Gaulard, H. Tilly, C. Haioun, 2017, European journal of cancer.

Hepatosplenic T-cell Lymphoma : Sinusal / Sinusoidal Localization of Malignant Cells Expressing the T-cell Receptor y 6

P. Gaulard, C. Haioun, F. Reyes, 2003 .

Confirmation of the Efficacy and Safety of Lenalidomide Oral Monotherapy in Patients with Relapsed or Refractory Mantle-Cell Lymphoma: Results of An International Study (NHL-003)

J. Vose, M. Czuczman, R. Bouabdallah, 2008 .

Phase II study of 3-hour infusion of high dose paclitaxel in refractory and relapsed aggressive non-Hodgkin's lymphomas. Groupe d'Etude des Lymphomes de l'Adulte.

J. Blay, A. Stamatoullas, B. Quesnel, 2000, Haematologica.

Phase II study of 3-hour infusion of high dose paclitaxel in refractory and relapsed aggressive non-Hodgkin ' s lymphomas

A. Stamatoullas, B. Quesnel, C. Haioun, 2000 .

Rituximab induction immunotherapy for first-line low-tumor-burden follicular lymphoma: survival analyses with 7-year follow-up.

G. Salles, H. Tilly, N. Brousse, 2012 .

Encouraging Activity of Obinutuzumab (GA101) Monotherapy in Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma: Results From a Phase II Study (BO20999),

G. Salles, R. Bouabdallah, P. Feugier, 2011 .

Randomized Phase III Trial Evaluating Subcutaneous Rituximab for the First-Line Treatment of Low–Tumor Burden Follicular Lymphoma: Results of a LYSA Study

K. Tarte, R. Houot, L. Xerri, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Baseline circulating tumour DNA and total metabolic tumour volume as early outcome predictors in aggressive large B‐cell lymphoma. A real‐world 112‐patient cohort

C. Copie-Bergman, P. Gaulard, C. Haioun, 2023, British journal of haematology.

Correction to: Quality of life of survivors 1 year after the diagnosis of diffuse large B-cell lymphoma: a LYSA study

F. Jardin, N. Mounier, C. Haioun, 2021, Annals of Hematology.

[Non epidermotropic T lymphoma preceded for several years by hypereosinophilic syndrome].

C. Bodemer, C. Haioun, M. Bagot, 1990, Annales de dermatologie et de venereologie.

Genetic overlap between autoimmune diseases and non‐Hodgkin lymphoma subtypes

J. Cerhan, N. Camp, G. Salles, 2019, Genetic epidemiology.

Phase II study of PEG-Intron in combination with chemotherapy for the treatment of first line patients with follicular lymphoma who need to be treated.

P. Feugier, C. Haioun, F. Bauduer, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Rituximab in combination with CHOP regimen in T-cell angioimmunoblastic lymphoma (AILD-TL) rich in large B cells. Favourable results in four patients.

P. Gaulard, A. Rahmouni, C. Haioun, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Anti-SARS-CoV-2 antibody response after 2 and 3 doses of BNT162b2 mRNA vaccine in patients with lymphoid malignancies

F. Lemonnier, C. Haioun, S. Gallien, 2022, Clinical Microbiology and Infection.

Clinical impact of contrast-enhanced computed tomography combined with low-dose 18F-fluorodeoxyglucose positron emission tomography/computed tomography on routine lymphoma patient management

A. Luciani, A. Rahmouni, C. Haioun, 2014, Leukemia & lymphoma.

Outcome of Immune Thrombocytopenia in Pregnancy: A French Nationwide Prospective Multicenter Observational Case-Control Study

C. Haioun, N. Costedoat-Chalumeau, J. Viallard, 2020 .

Whole-body diffusion-weighted magnetic resonance imaging with apparent diffusion coefficient mapping for staging patients with diffuse large B-cell lymphoma

Alexandre Vignaud, Pierre Brugières, Emmanuel Itti, 2010, European Radiology.

POLA‐R‐CHP: POLATUZUMAB VEDOTIN COMBINED WITH RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN, PREDNISONE FOR PATIENTS WITH PREVIOUSLY UNTREATED DIFFUSE LARGE B‐CELL LYMPHOMA

C. Haioun, N. Bartlett, C. Lee, 2017 .

Angioimmunoblastic T-Cell Lymphoma (AITL) Is the Most Prevalent T-Cell Lymphoma Entity in Western Europe

T. Molina, P. Gaulard, F. Berger, 2012 .

Congenital Erythropoietin-Dependent Erythrocytosis Responsive to Theophylline Treatment

J. Pawlotsky, D. Dhumeaux, C. Haioun, 1998 .

Liver transplantation for fulminant hepatitis following chemotherapy for malignant lymphoma

D. Dhumeaux, C. Haioun, E. Zafrani, 1990, The Lancet.

Combining gene expression profiling and machine learning to diagnose B-cell non-Hodgkin lymphoma

C. Copie-Bergman, T. Molina, F. Jardin, 2020, Blood Cancer Journal.

Efficiency of In Vivo Purging With Rituximab Followed by High-Dose Therapy With Autologous Peripheral Blood Stem Cell Transplantation in B-Cell Non-Hodgkin’s Lymphomas: A Single-Institution Study

P. Gaulard, C. Haioun, F. Reyes, 2001 .

Prognostic value of pretherapy metabolic tumor volume (MTV) and total lesion glycolysis (TLG) in patients with diffuse large B-cell lymphoma (DLBCL)

H. Tilly, C. Haioun, A. Biggi, 2012 .

Epoetin beta treatment of chemotherapy induced anemia in cancer patients: Results of a large prospective cohort study

S. Mathoulin-Pélissier, I. Ray-Coquard, C. Haioun, 2007 .

Switching From Romiplostim to Eltrombopag or Vice Versa for Immune Thrombocytopenia: Efficacy and Safety in 46 Patients

F. Jardin, P. Bierling, C. Haioun, 2012 .

Comparison of clinical scoring systems in aggressive B-cell lymphomas (BCL): An individual patient-level analysis across international trials (SEAL).

M. Ziepert, G. Salles, C. Flowers, 2019, Journal of Clinical Oncology.

Patients with plasma cell disorders examined at whole-body dynamic contrast-enhanced MR imaging: initial experience.

A. Luciani, A. Rahmouni, J. Deux, 2009, Radiology.

Early 18fluorodeoxyglucose PET Scan as a Prognostic Tool in Diffuse Large B-Cell Lymphoma Patients Treated with An Anthracycline-Based Chemotherapy Plus Rituximab.

F. Jardin, H. Tilly, C. Haioun, 2009 .

Diagnosis-to-Treatment Interval (DTI) Remains Associated with Adverse Clinical Characteristics and Outcome in Newly Diagnosed Patients with Diffuse Large B-Cell Lymphoma Treated on Clinical Trials

J. Cerhan, T. Molina, G. Salles, 2017 .

Lenalidomide in combination with R-CHOP (R2-CHOP) in patients with high burden follicular lymphoma: phase 2 study.

T. Molina, G. Salles, R. Bouabdallah, 2013, Clinical advances in hematology & oncology : H&O.

Treatment with Hypomethylating Agent 5-Azacytidine Induces Sustained Response in Angioimmunoblastic T Cell Lymphomas

P. Gaulard, F. Lemonnier, C. Haioun, 2016 .

Efficacy and safety of lenalidomide oral monotherapy in patients with relapsed or refractory mantle-cell lymphoma: Results from an international study (NHL-003).

J. Vose, M. Czuczman, R. Bouabdallah, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The Efficacy and Safety of Lenalidomide Oral Monotherapy in Patients with Mantle Cell Lymphoma Previously Treated with Bortezomib: Pooled Data from Two Phase II Studies (NHL-002 and NHL-003).

J. Vose, M. Czuczman, R. Bouabdallah, 2008 .

Venetoclax induces profound and sustained responses in patients with relapsed/refractory light‐chain amyloidosis

F. Lemonnier, C. Haioun, A. Maarek, 2021, British journal of haematology.

Daratumumab is safe and induces a rapid hematological response in light-chain amyloidosis with severe cardiac impairment

F. Lemonnier, C. Haioun, A. Maarek, 2020, Leukemia & lymphoma.

Rituximab compared to observation after high-dose consolidative first-line chemotherapy (HDC) with autologous stem cell transplantation in poor-risk diffuse large B-cell lymphoma: Updated results of the LNH98-B3 GELA study

B. Coiffier, H. Tilly, C. Gisselbrecht, 2007 .

Rituximab Combined to ACVBP (R-ACVBP) as a New Inductive Treatment Followed by High-Dose Consolidative Autotransplantation (HDC) for Poor Risk Diffuse Large B-Cell Lymphoma (DLBCL) in First-Line. Preliminary Results on 119 Patients of a GELA Phase II Study.

B. Coiffier, O. Casasnovas, H. Tilly, 2006 .

[Systemic capillary leak syndrome disclosing mixed diffuse T lymphoma].

C. Haioun, M. Bagot, J. Revuz, 1991, Annales de dermatologie et de venereologie.

Final Results of a Randomized Phase 2 Multicenter Study of Two Bortezomib Schedules In Patients with Recurrent or Refractory Follicular Lymphoma. Groupe d'Etude Des Lymphomes De l'Adulte (GELA) Study FL-05

B. Coiffier, R. Bouabdallah, O. Casasnovas, 2010 .

Venetoclax induces sustained complete responses in refractory/relapsed patients with cardiac AL amyloidosis.

F. Lemonnier, C. Haioun, A. Maarek, 2019, Journal of Clinical Oncology.

Efficacy and Safety of Thalidomide In Mantle Cell Lymphoma: Results of the French ATU Program.

C. Haioun, O. Hermine, B. Arnulf, 2010 .

S1600 REAL-WORLD RESULTS ON CD19 CAR T-CELL FOR 60 FRENCH PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA INCLUDED IN A TEMPORARY AUTHORIZATION FOR USE (ATU) PROGRAM

R. Houot, G. Salles, H. Tilly, 2019, HemaSphere.

Epstein–Barr virus‐associated B‐cell lymphoproliferative disorder in a patient with Sézary syndrome treated by methotrexate

C. Haioun, O. Chosidow, N. Ortonne, 2016, The British journal of dermatology.

Diffuse large B-cell lymphoma of Waldeyer's ring has distinct clinicopathologic features: a GELA study.

C. Copie-Bergman, M. Baia, T. Molina, 2012 .

Reliable subtype classification of diffuse large B-cell lymphoma samples from GELA LNH2003 trials using the Lymph2Cx gene expression assay

Philippe Ruminy, David Gentien, Randy D Gascoyne, 2017, Haematologica.

Functional Imaging in Lymphoma

A. Luciani, T. Yen, A. Rahmouni, 2014 .

lmmunoblastic Lymphoma Involving the Bone Marrow in a Patient With Alpha Chain Disease

C. Haioun, F. Reyes, M. Tulliez, 2006 .

Low Suvmax Measured on Baseline FDG-PET/CT and Elevated β2 Microglobulin Are Negative Predictors of Outcome in High Tumor Burden Follicular Lymphoma Treated By Immunochemotherapy: A Pooled Analysis of Three Prospective Studies

G. Salles, M. Federico, H. Tilly, 2016 .

Structural profiles of TP 53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma : an international collaborative study

L. Staudt, A. Rosenwald, W. Chan, 2008 .

Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation.

G. Salles, A. Stamatoullas, N. Brousse, 2001, Blood.

Doxorubicin-containing regimen with or without interferon alfa-2b for advanced follicular lymphomas: final analysis of survival and toxicity in the Groupe d'Etude des Lymphomes Folliculaires 86 Trial.

J. Rossi, B. Coiffier, R. Bouabdallah, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte.

H. Tilly, N. Brousse, É. Lepage, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A PHASE II LYSA STUDY OF OBINUTUZUMAB COMBINED WITH LENALIDOMIDE FOR RELAPSED OR REFRACTORY FOLLICULAR B‐CELL LYMPHOMA

R. Houot, G. Salles, R. Bouabdallah, 2017 .

Phase II study of single-agent copanlisib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

G. Salles, G. Lenz, K. Ardeshna, 2017 .

Central nervous system relapse in younger patients with diffuse large B-cell lymphoma: a LYSA and GLA/DSHNHL analysis

A. Rosenwald, M. Ziepert, T. Molina, 2023, Blood advances.

Updated Report on Identification of Molecular Predictors of Tazemetostat Response in an Ongoing NHL Phase 2 Study

J. Gribben, G. Salles, J. Radford, 2018, Blood.

Impact of [18F]Fluorodeoxyglucose Positron Emission Tomography Response Evaluation in Patients With High–Tumor Burden Follicular Lymphoma Treated With Immunochemotherapy: A Prospective Study From the Groupe d’Etudes des Lymphomes de l’Adulte and GOELAMS

G. Salles, L. Xerri, P. Feugier, 2012 .

Recurrent Mutations of the Exportin 1 Gene (XPO1) in Primary Mediastinal B-Cell Lymphoma: A Lysa Study

C. Copie-Bergman, T. Molina, F. Jardin, 2015 .

Complete remission of gastric Burkitt's lymphoma after eradication of Helicobacter pylori.

I. Sobhani, C. Copie-Bergman, M. Baia, 2009, World journal of gastroenterology.

Interim [18F]fluorodeoxyglucose positron emission tomography scan in diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy plus rituximab.

C. Copie-Bergman, F. Jardin, A. Rahmouni, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Influence of clinical status on the efficiency of stored platelet transfusion

C. Haioun, C. Cordonnier, M. Kuentz, 1994, British journal of haematology.

Phase 3 trial of subcutaneous epcoritamab + R-CHOP versus R-CHOP in patients (pts) with newly diagnosed diffuse large B-cell lymphoma (DLBCL): EPCORE DLBCL-2.

L. Sehn, G. Lenz, C. Haioun, 2023, Journal of Clinical Oncology.

Safety and efficacy of PD-L1 inhibitor durvalumab with R-CHOP or R2-CHOP in subjects with previously untreated, high-risk DLBCL.

R. Greil, U. Jäger, L. Trümper, 2019, Journal of Clinical Oncology.

IPI24: An International Study To Create An IPI For The Event-Free Survival At 24 Months (EFS24) Endpoint For DLBCL In The Immunochemotherapy Era

J. Cerhan, T. Molina, G. Salles, 2013 .

[Primary cutaneous lymphoma, with the exception of mycosis fungoides].

C. Haioun, M. Bagot, J. Revuz, 1992, Annales de dermatologie et de venereologie.

A Multicenter, Case-Control Study Evaluating the Characteristics and Outcome of ITP Patients Refractory to, Rituximab, Splenectomy and Both TPO Receptor Agonists

G. Salles, C. Haioun, I. Durieu, 2015 .

Structural profiles of TP 53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma : an international collaborative study

L. Staudt, A. Rosenwald, W. Chan, 2008 .

Responses to second-line tyrosine kinase inhibitors are durable: an intention-to-treat analysis in chronic myeloid leukemia patients.

L. Staudt, A. Rosenwald, T. Greiner, 2012, Blood.

SGN-30 (Anti-CD30 mAb) Has a Single-Agent Response Rate of 21% in Patients with Refractory or Recurrent Systemic Anaplastic Large Cell Lymphoma (ALCL).

J. Leonard, B. Cheson, H. Holte, 2006 .

Influence of translocation t(11;18) on response to conservative treatment of MALT gastric lymphoma (MGL)

C. Copie-Bergman, P. Gaulard, K. Leroy, 2003 .

Clinical Trials and Observations

C. Bloomfield, L. Staudt, A. Rosenwald, 2005 .

Primary bone diffuse large B-cell lymphoma: a retrospective evaluation on 76 cases from French institutional and LYSA studies

D. Biau, G. Salles, H. Tilly, 2016, Leukemia and Lymphoma.

The Prognostic Impact of CD163-Positive Macrophages in Follicular Lymphoma: A Study from the BC Cancer Agency and the Lymphoma Study Association

R. Gascoyne, D. Scott, G. Salles, 2015, Clinical Cancer Research.

The Prognostic Impact of Cd163-positive Macrophages in Follicular Lymphoma: a Study from the Bc Cancer Agency and the Lymphoma Study Association. Kridel Et Al Follicular Lymphoma-associated Macrophages Kridel Et Al Follicular Lymphoma-associated Macrophages

R. Gascoyne, L. Sehn, J. Connors, 2022 .

Follicular Peripheral T-cell Lymphoma Expands the Spectrum of Classical Hodgkin Lymphoma Mimics

C. Copie-Bergman, P. Gaulard, S. Swerdlow, 2012, The American journal of surgical pathology.

Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Diffuse Large B-Cell Lymphoma: An Individual Patient-Level Analysis of Multiple Randomized Trials (SEAL).

M. Ziepert, N. Schmitz, C. Flowers, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

B. Coiffier, C. Haioun, J. Gabarre, 2013, European journal of cancer.

Nonrelapse mortality after CAR T-cell therapy for large B-cell lymphoma: a LYSA study from the DESCAR-T registry

R. Houot, O. Casasnovas, M. Mohty, 2023, Blood advances.

Interim [18F]fluorodeoxyglucose positron emission tomography scan in diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy plus rituximab.

C. Copie-Bergman, F. Jardin, A. Rahmouni, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma.

B. Coiffier, J. Jais, C. Haioun, 2011, Blood.

High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma.

W. Klapper, F. Jardin, E. Hoster, 2015, Blood.

Peripheral T-cell Lymphomas With a Follicular Growth Pattern are Derived From Follicular Helper T Cells (TFH) and may Show Overlapping Features With Angioimmunoblastic T-cell Lymphomas

C. Copie-Bergman, P. Gaulard, T. Marafioti, 2009, The American journal of surgical pathology.

Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study.

J. Rossi, G. Salles, R. Bouabdallah, 2008, Blood.

Obinutuzumab plus Lenalidomide (GALEN) for the treatment of relapse/refractory aggressive lymphoma: a phase II LYSA study

R. Houot, G. Salles, P. Feugier, 2018, Leukemia.

Lymphoma Obinutuzumab plus Lenalidomide ( GALEN ) for the treatment of relapse / refractory aggressive lymphoma : a phase II LYSA study

R. Houot, P. Feugier, H. Tilly, 2018 .

G. Salles, L. Xerri, P. Feugier, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

GLOFITAMAB STEP‐UP DOSING: UPDATED EFFICACY DATA SHOW HIGH COMPLETE RESPONSE RATES IN HEAVILY PRETREATED RELAPSED/REFRACTORY (R/R) NON‐HODGKIN LYMPHOMA (NHL) PATIENTS

E. Piccione, C. Haioun, C. Carlo-Stella, 2021, Hematological Oncology.

Atezolizumab + obinutuzumab + venetoclax in patients with relapsed or refractory indolent non-Hodgkin’s lymphoma (R/R iNHL): Primary analysis of a phase 2 trial from LYSA.

K. Tarte, R. Houot, R. Bouabdallah, 2021 .

A gene-expression profiling score for outcome prediction disease in patients with follicular lymphoma: a retrospective analysis on three international cohorts

J. Cerhan, K. Tarte, F. Jardin, 2018, The Lancet. Oncology.

High PDL1/PDL2 gene expression correlates with worse outcome in primary mediastinal large B-cell lymphoma

F. Jardin, P. Gaulard, H. Tilly, 2023, Blood advances.

Rituximab exposure is influenced by baseline metabolic tumor volume and predicts outcome of DLBCL patients: a Lymphoma Study Association report.

G. Salles, O. Casasnovas, P. Feugier, 2017, Blood.

Rituximab exposure is influenced by baseline metabolic tumor volume and predicts outcome of DLBCL patients: a Lymphoma Study

O. Casasnovas, P. Feugier, C. Haioun, 2020 .

Personalized risk prediction for event‐free survival at 24 months in patients with diffuse large B‐cell lymphoma

J. Cerhan, R. Gascoyne, C. Copie-Bergman, 2016, American journal of hematology.

Diagnostic yield of bronchoalveolar lavage in pneumonitis occurring after allogeneic bone marrow transplantation.

C. Haioun, J. Bernaudin, D. Payen, 1985, The American review of respiratory disease.

Whole exome sequencing of relapsed/refractory patients expands the repertoire of somatic mutations in diffuse large B‐cell lymphoma

C. Copie-Bergman, F. Jardin, G. Salles, 2016, Genes, chromosomes & cancer.

Comparison of autografting using mobilized peripheral blood stem cells with and without granulocyte colony-stimulating factor in malignant lymphomas.

C. Haioun, F. Reyes, P. Brice, 1994, Bone marrow transplantation.

Safety of prophylactic use of darbepoetin alfa in patients with diffuse large B-Cell lymphoma (DLBCL) treated with R-CHOP 14 or RCHOP21: Preliminary results of the LNH03-6B randomized GELA study.

B. Coiffier, H. Tilly, C. Gisselbrecht, 2006 .

Autologous Stem Cell Transplantation (auto-SCT) as the Treatment of Choice for Follicular Lymphoma Patients in First Relapse: Final Analysis of the Outcome of 175 Patients Treated in the GELA/GOELAMS FL 2000 Study

G. Salles, C. Volteau, C. Haioun, 2008 .

Febrile Neutropenia Risk Assessment and Granulocyte-Colony Stimulating Factor Support in Patients with Diffuse Large B Cell Lymphoma Receiving R-CHOP Regimens.

A. Salar, U. Jaeger, H. Johnsen, 2009 .

A Phase 1b Study of Blinatumomab Including Subcutaneous Administration in Relapsed / Refractory (R/R) Indolent Non Hodgkin's Lymphoma (NHL)

S. Ferrari, C. Haioun, C. Tam, 2021, Blood.